This article is a correction to:
Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
Argyrios Tzouvelekis1,2*†‡
Theodoros Karampitsakos3†Paschalis Ntolios4
Vasilios Tzilas1Evangelos Bouros1Evangelos Markozannes1Ioanna Malliou1Aris Anagnostopoulos1Andreas Granitsas1Paschalis Steiropoulos2
Katerina Dimakou3
Serafeim Chrysikos4
Nikolaos Koulouris1
Demosthenes Bouros1‡
- 1First Academic Department of Pneumonology, Hospital for Diseases of the Chest “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
- 2Division of Immunology, Biomedical Sciences Research Center “Alexander Fleming”, Athens, Greece
- 35th Respiratory Department, Hospital for Diseases of the Chest “Sotiria”, Athens, Greece
- 4Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, Komotini, Greece
A corrigendum on
In the original article, there was a mistake in Figure 1 as published [x and y axes were mislabeled and ⋆p-value <0.05 indicating significance was missing]. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
FIGURE 1
Figure 1. Changes in %forced vital capacity (ΔFVC) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.
In the original article, there was a mistake in Figure 2 as published [x and y axes were mislabeled and ⋆p-value <0.05 indicating significance was missing]. The corrected Figure 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
FIGURE 2
Figure 2. Changes in %diffusion capacity of lung for carbon monoxide (ΔDLCO) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.
The original article was updated.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: pirfenidone, safety, efficacy, idiopathic pulmonary fibrosis, treatment
Citation: Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N and Bouros D (2018) Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Front. Med. 4:257. doi: 10.3389/fmed.2017.00257
Received: 06 December 2017; Accepted: 22 December 2017;
Published: 24 January 2018
Edited and Reviewed by: Mehdi Mirsaeidi, University of Miami, United States
Copyright: © 2018 Tzouvelekis, Karampitsakos, Ntolios, Tzilas, Bouros, Markozannes, Malliou, Anagnostopoulos, Granitsas, Steiropoulos, Dimakou, Chrysikos, Koulouris and Bouros. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Argyrios Tzouvelekis, argyrios.tzouvelekis@fleming.gr
†These authors have contributed equally to this work.
‡These authors jointly supervised the work.